Convexity Labs

HIPO

Convexity Analyst · HIPO
low confidenceTactical · no named thesis
Generated Jun 21, 2026

Analyst Note: HIPO (Hippo Holdings Inc.)

Date: 2026-06-13 Current Price: $25.96

1. Structural Readiness

  • State: Context-only
  • Conservative Entry:
  • Breakout Level:
  • Extension:
  • Classification: INVALIDATED / NOT FORMING

2. Thesis Layer

  • Thesis Classification: TACTICAL / SETUP-LED
  • Analysis: As of 2026-06-13, there is no named secular thesis attached to this specific setup in the source data. The name is not currently being driven by a macro-structural narrative (e.g., "AI-driven insurance disruption" or "Rate-cycle recovery") in the provided context.
  • Judgment Criteria: The investment case must be judged strictly on the quality of the technical setup (which is currently undefined) and the fundamental business trajectory recorded by management. Do not invent a macro thesis to justify the position. The conviction must rest on whether the company is executing its stated 2028 targets and if the technical structure eventually forms a valid entry point.

3. Business Overview

  • Company Description: Hippo Holdings Inc. is a technology-native insurance holding company operating as a multi-carrier platform. It provides property and casualty (P&C) insurance products to individuals and businesses primarily in the United States.
  • Business Model: The company operates through a hybrid model:
  • Owned MGA: Directly underwriting risk.
  • Partner MGAs: Providing insurance capacity, regulatory licenses, and reinsurance access to third-party Managing General Agents (MGAs).
  • Services: Offering fee-based and commission-based services for policy placement and servicing.
  • Key Operations & Evidence (as of 2026-04-30):
  • Premium Growth: The company generated $332 million in gross written premium (GWP) in the quarter ended March 31, 2026, a 58% increase year-over-year (E6).
  • Line Mix Diversification: The portfolio is shifting away from pure homeowners exposure. Casualty lines generated $101 million (30% of total GWP, up from 16% last year), and Commercial Multi-Peril (CMP) generated $96 million (29% of total GWP, up from 24% last year) (E7).
  • Guidance & Targets: Management is targeting $2 billion in GWP by 2028, $125 million in adjusted net income, and an 18% adjusted ROE (E1).
  • 2026 Outlook: Management raised full-year GWP guidance to $1.45–$1.525 billion (up from $1.4–$1.5 billion) and net written premium to $520–$550 million (E2, E3).
  • Underwriting Discipline: The company maintains a net combined ratio guidance of 103%–105%, inclusive of a 13% catastrophe loss ratio, acknowledging elevated CAT quarters in Q2/Q3 (E4).
  • Capital & Risk Management: Hippo maintains a comprehensive reinsurance program and has strategically retained more risk in its MGA portfolio by scaling back proportional reinsurance, reflecting confidence in underwriting performance (E14, E15).
  • Financial Position: As of year-end 2025, stockholders' equity was $436.1 million (E21).

4. Archetype and Conviction

  • Archetype: Growth Leader
  • *Fit:* The company is demonstrating rapid top-line expansion (58% GWP growth in Q1 2026) while simultaneously improving its line mix to include higher-margin commercial lines (Casualty and CMP). The management guidance reflects a clear path to profitability ($125M net income target) and capital efficiency (18% ROE target).
  • Valuation Context:
  • Forward consensus EPS for FY1 is $0.33 and FY2 is $1.03 (E28).
  • At a current price of $25.96, the stock trades at approximately 78x FY1 EPS and 25x FY2 EPS. This implies the market is pricing in significant acceleration in earnings growth to justify the multiple, consistent with a "Growth Leader" archetype rather than a value or deep recovery play.
  • Conviction Stack:
  • Thesis Strength: Low (No named secular thesis; purely tactical).
  • Evidence Quality: High (Strong, specific guidance updates from April 2026 earnings).
  • Setup Readiness: None (No breakout or forming coil identified).
  • Rerating Potential: Dependent on the successful execution of the 2028 targets and the eventual formation of a technical setup.

5. Invalidations, Strengths, and Gaps

  • What Would Invalidate:
  • A failure to maintain the combined ratio within the 103%–105% range, particularly if catastrophe losses exceed the 13% assumption.
  • A significant slowdown in GWP growth below the $1.45 billion annualized run rate.
  • What Would Strengthen:
  • Continued outperformance in the Commercial Multi-Peril and Casualty segments, further reducing reliance on homeowners exposure.
  • Confirmation of the $125 million adjusted net income target ahead of the 2028 timeline.
  • Gaps in Evidence:
  • Sector Specifics: The "Industry" field is blank; while "Financial Services" is noted, specific sub-sector peer comparisons are missing.
  • Cash Flow: While equity and earnings are mentioned, specific free cash flow generation details for the quarter are not explicitly detailed in the provided evidence block.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: low Key evidence: 58% year-over-year gross written premium growth in Q1 2026; Management raised full-year GWP guidance to $1.45-$1.525 billion; Strategic shift to commercial lines (Casualty and CMP) now comprising 59% of total GWP. Expected path: Management expects to reach $2B GWP and $125M net income by 2028; the company plans to continue diversifying away from homeowners exposure to reduce catastrophe risk. Expected horizon: 12-24 months for fundamental targets to materialize; technical setup horizon is undefined until structure forms.

Loading chart...
Exhibit 1: HIPO daily candlestick — no active setup overlay.

Source-backed evidence anchors and catalysts land once Convexity finishes coverage for HIPO.

Core assumptions for this name haven't been articulated yet — they land alongside the rerating thesis.

Value picture unavailable — no financial spine on file for HIPO.

Layer B fundamentals snapshot not yet available. Highlights land once Convexity finishes the classification.

Coverage: